Masitinib is a first in class oral kinase inhibitor having a breakthrough mechanism of action by selectively targeting mast cells and macrophages/microglia.

Based on this mechanism of action, masitinib addresses several indications in neurology, inflammatory, and oncology diseases. Certain indications pursued with masitinib have blockbuster potential (COVID-19, Alzheimer’s disease, multiple sclerosis, severe asthma, prostate cancer), whereas others are orphan diseases (amyotrophic lateral sclerosis, indolent systemic mastocytosis and pancreatic cancer).